Details of Disease

General Information of Disease (ID: DISI0V5E)

• Disease Name: Glioblastoma
• Synonyms: gliosarcoma (histologic variant); giant cell glioblastoma (histologic variant); grade IV adult astrocytic tumor; grade IV adult astrocytic tumour; GBM (glioblastoma); glioblastoma multiforme (disease); GBM; grade IV astrocytic tumour; grade IV astrocytic tumor; spongioblastoma multiforme; glioblastoma; primary glioblastoma multiforme; glioblastoma (disease); glioblastoma multiforme; WHO grade IV glioma; grade IV astrocytoma; grade IV astrocytic neoplasm
• Disease Class: 2A00: Brain cancer
• Definition: The most malignant astrocytic tumor (WHO grade IV). It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma, IDH-mutant), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma, IDH- wildtype). (Adapted from WHO)
• Disease Hierarchy:
  DISMP7I5: High grade astrocytic tumor
  DISI0V5E: Glioblastoma
• ICD Code: ICD-11: ICD-11: 2A00
• Disease Identifiers:
  MONDO ID: MONDO_0018177
  MESH ID: D005909
  UMLS CUI: C0017636
  MedGen ID: 42228
  Orphanet ID: 360

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 9 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aminolevulinic acid hci	DMS4BLQ	Approved	Small molecular drug	[1]
Bevacizumab	DMSD1UN	Approved	Monoclonal antibody	[2]
Cyclophosphamide	DM4O2Z7	Approved	Small molecular drug	[3]
Dacarbazine	DMNPZL4	Approved	Small molecular drug	[4]
Dasatinib	DMJV2EK	Approved	Small molecular drug	[5]
Gefitinib	DM15F0X	Approved	Small molecular drug	[6]
Imiquimod	DM1TMA3	Approved	Small molecular drug	[7]
Memantine	DMD9WSC	Approved	Small molecular drug	[8]
Temozolomide	DMKECZD	Approved	Small molecular drug	[9]

This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
TVI-Brain-1	DMV5MED	Phase 2/3	Vaccine	[10]
Synthetic survivin peptide vaccine	DM0SECE	Phase 2	Vaccine	[11]
IGV-001	DM1KL69	Phase 1	Vaccine	[12]
RG6156	DMPKZX7	Phase 1	Bispecific antibody	[13]
rhenium-186	DMH4HEW	Phase 1	Small molecule	[14]

This Disease is Treated as An Indication in 1 Investigative Agents

Drug Name	Drug ID	Highest Status	Drug Type	REF
Valproic Acid	DMS49KH	Investigative	Small molecular drug	[15]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Comparison of commercial 5-aminolevulinic acid (Gliolan?) and the pharmacy-compounded solution fluorescence in glioblastoma. Acta Neurochir (Wien). 2019 Aug;161(8):1733-1741.
• [2] Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733-40.
• [3] Cyclophosphamide FDA Label
• [4] Dacarbazine FDA Label
• [5] Dasatinib FDA Label
• [6] Gefitinib FDA Label
• [7] Imiquimod FDA Label
• [8] Memantine FDA Label
• [9] Temozolomide FDA Label
• [10] ClinicalTrials.gov (NCT05685004) Randomized Phase 2b Study of Safety And Efficacy Of TVI-Brain-1 Combined With Conformal Radiotherapy And Temozolomide Vs Standard Therapy In Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM). U.S.National Institutes of Health.
• [11] ClinicalTrials.gov (NCT05163080) Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE). U.S.National Institutes of Health.
• [12] ClinicalTrials.gov (NCT04485949) A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma. U.S.National Institutes of Health.
• [13] Clinical pipeline report, company report or official report of Roche
• [14] ClinicalTrials.gov (NCT05460507) A Single Arm Open Label Study to Determine the Safety and Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Recurrence of Glioma in Patients Who Received a Prior Treatment With 186RNL. U.S.National Institutes of Health.
• [15] Valproic Acid FDA Label